Weakness in pot stocks scuttles MedMen’s acquisition of PharmaCann
A weakness in pot stocks has scuttled MedMen Enterprises Inc.’s planned acquisition of PharmaCann less than a month after it received antitrust approval. The Los Angeles-based cannabis company said Tuesday that it will terminate the all-share deal, which was valued at $682 million when it was announced last October and MedMen was trading at about […]